Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Onvansertib
Cardiff Oncology
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Opevesostat, -, CABAZITAXEL , -, FLUDROCORTISONE , Olaparib, HYDROCORTISONE , DEXAMETHASONE , -, -, -, -, Olaparib, DOCETAXEL , -
Merck Sharp and Dohme
Metastatic castration resistant prostate cancer (mCRPC)
1 trial -
Osimertinib + Savolitinib
AstraZeneca
Non-Small Cell Lung Cancer
1 trial -
Osimertinib 80 mg/40 mg
AstraZeneca
Stage II-IIIB Non-small Cell Lung Carcinoma
1 trial -
PACLITAXEL, MYCOPHENOLATE MOFETIL, volrustomig, INFLIXIMAB, FLUOROURACIL, CISPLATIN
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB
AstraZeneca AB
Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)
1 trial -
PARACETAMOL, DIPHENHYDRAMINE, INFLIXIMAB, TOCILIZUMAB, AZD7789, EPINEPHRINE
AstraZeneca AB
Relapsed/Refractory Classical Hodgkin Lymphoma
1 trial -
POMALIDOMIDE , ELRANATAMAB, AZD0305, ELRANATAMAB
AstraZeneca AB
Multiple Myeloma
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Castration-resistant Prostate Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Placebo for AZD2693 Solution for Injection, Placebo for AZD2693 Solution for Injection
AstraZeneca AB
Non-cirrhotic non-alcoholic steatohepatitis with fibrosis
1 trial -
Placebo for AZD4144, AZD4144
AstraZeneca AB
Sepsis-associated acute kidney injury (AKI)
1 trial -
Placebo for AZD5148, AZD5148
AstraZeneca AB
Recurrence of Clostridioides difficile Infection
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation
Novartis Pharmaceuticals
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
1 trial -
REGN15505
Regeneron UK Limited
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
REGN4336
Regeneron UK Limited
Metastatic Castration-resistant Prostate Cancer
1 trial -
REGN5678
Regeneron UK Limited
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
RITUXIMAB, CYCLOPHOSPHAMIDE , AZD0486, PREDNISOLONE , VINCRISTINE , Calquence 100 mg film-coated tablets, RITUXIMAB , AZD0486, DOXORUBICIN , Calquence 100 mg film-coated tablets, PREDNISONE , AZD0486, AZD0486
AstraZeneca AB
Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
1 trial -
Rilvegostomig, Rilvegostomig
AstraZeneca AB
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).
1 trial -
SELUMETINIB, SELUMETINIB, Selumetinib, Selumetinib
AstraZeneca AB
Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
1 trial -
SRF617
Arcus Biosciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
SX-682
United Therapeutics Europe Ltd
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
1 trial -
Saruparib
AstraZeneca AB
Advanced/Recurrent Ovarian cancer
1 trial -
Saruparib, Camizestrant, Datopotamab deruxtecan, PACLITAXEL , Saruparib, DS-8201a, Saruparib, Saruparib
AstraZeneca AB
Advanced Solid Tumors
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources